This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mentor Plots Cosmetic Change

One question posed during a telephone conference Monday was whether Mentor might make a hostile run at Medicis. Mentor CEO Levine declined to comment, saying only that his company "will wait for the dust to settle" before making the next step. The offer to Medicis was the only way to get that company's attention because of its dealing with Inamed, Levine said.

Medicis shareholders are scheduled to vote on the Inamed deal on Dec. 19. The transaction is under review by the Federal Trade Commission.

Mentor's Dilemma

Mentor's future appeal to investors will depend on how fast it gets U.S. approval for silicone breast implants for cosmetic uses, what price it gets for the urology businesses and how it can expand its presence in the skin-treatment market. Buying Medicis would easily answer the skin-care question.

Inamed and Mentor are dueling to be first on the U.S. market with silicone gel breast implants for cosmetic purposes. Both have received conditional approval from the Food and Drug Administration for their products, but they haven't said what they must do to secure final approval.

In the past, analysts speculated that the company getting to the market first would have an advantage, but now many believe the FDA will grant final approval at essentially the same time.

Mentor says a merger with Medicis will enable their combined sales forces to increase product offerings to cosmetic surgeons and dermatology specialists.

Because so-called aesthetics medicine is a "significant growth opportunity," Mentor said last month that it was evaluating alternatives for its urology business, meaning that if the price is right, it will sell.

Mentor's urology businesses, including urinary catheters, erectile dysfunction products and prostate cancer products, yielded $116.7 million in sales for the six months ended Sept. 30. Aesthetics products, mainly breast implants, but also skin and body products, delivered $132.8 million.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MRX $0.00 0.00%
IMDC $0.02 0.00%
AGN $319.98 -0.09%
AAPL $117.82 -0.18%
FB $105.47 0.06%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs